The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Optimizing supportive care after completion of CLL treatment
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses supportive care considerations following completion of chronic lymphocytic leukemia (CLL) treatment. She highlights the importance of revisiting routine cancer screening and vaccinations after treatment, including considering vaccination around 6-12 months after anti-CD20-based therapy as B-cell recovery occurs. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
